Anti-PD-1 and Chemotherapy for R/R Hodgkin Lymphoma

Hospices Civils de Lyon30 enrolled

Overview

Anti-PD-1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV), but median progression free survival (PFS) is only one year. The efficacy of treatment following anti-PD-1 is not well known. In this context, the optimal treatment for patients who failed after anti-PD-1 therapy is an issue. To better assess their outcome, the investigators retrospectively analyzed the characteristics and outcome of patients from 14 LYSA (The Lymphoma Study Association) centers who lost response to anti-PD-1 therapy and received additional CT.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hodgkin Lymphoma

Interventions

Evaluate the improvement in response from the end of anti-PD-1 monotherapyBIOLOGICAL

Evaluate the improvement in response from the end of anti-PD-1 monotherapy to the first evaluation after introduction of CT alone (Group 1) or combined with anti-PD-1 (Group 2).

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Initial diagnosis of classical HL * Optional histopathology confirmation of relapse/refractory HL, (2) age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) Performance Status from 0 to 2 * Patients must be have received: at least 2 prior regimens and have received or be ineligible for autologous stem cell transplant and must have received prior BV, and at least 2 cycles of single agent anti-PD-1 as last treatment before entering the study, * Patients must have inadequate response to anti-PD-1 monotherapy (progressive disease or partial response according to Lugano criteria) with at least one hypermetabolic lesion over the liver and mediastinum background at time of inclusion in the study * Previous allogeneic stem cell transplant was allowed. Patients treated with radiotherapy alone after anti-PD1 or combined with anti-PD1 treatment were not included in the study. Exclusion Criteria: \- radiotherapy in the treatment after anti-PD1

Locations (1)

Centre Hospitalier Lyon Sud

Pierre-Bénite, France

Outcomes

Primary Outcomes

Overall response rate after re-exposure to chemotherapy

Patient evaluation was timed by treating physicians according to the policy of each center, and all patients were evaluated after a median of 10 weeks (min 7 weeks, max 12 weeks) with PET/CT using Lugano criteria

Time frame: 10 weeks

Secondary Outcomes

Best response obtained (Group 1)

the best response obtained with CT after anti-PD-1

Time frame: 10 weeks

Best response obtained (Group 2)

the best response obtained with CT after the combination anti-PD-1 and CT

Time frame: 10 weeks

The toxicities experienced during CT or anti-PD-1 plus CT combination

The toxicities were graded retrospectively according to the National Cancer Institute Common Toxicity Criteria for AEs (version 4.0).

Time frame: 10 weeks

Outcomes including PFS

PFS was defined as the time from first relapse, or progression, to the next event (defined as either second relapse/progression, change of therapy, or death from any cause)

Time frame: up to 12 months

Outcomes including overall survival (OS).

OS was defined as the time from first relapse, or progression, to death from any cause.

Time frame: up to 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.